Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
CellaVision AB revises its financial target for operating margin from 15% to 20% over an economic cycle. | ||
By: Nasdaq / GlobeNewswire - 03 Jul 2015 | Back to overview list |
|
This information was released for public disclosure on July 3, 2015 at 08.20 pm CET. CellaVision revises its financial target regarding the operating margin from 15% to 20% over an economic cycle. This is primarily done because of CellaVision scalable and cost-effective business model. CellaVision has also released information to the public today regarding a follow-up order in excess of SEK 30 million from a veterinary laboratory chain in the US market in 2015. However the company foresees that sales in the second quarter of 2015 will be somewhat lower than the strong comparative quarter of 2014. In view of the above CellaVision chooses to inform the market in this particular case that CellaVision's expected operating income, EBIT for the full year 2015, will exceed SEK 65 million. "The main reason for revising our target to 20% in operating margin is the scalable business model where CellaVision primarily sells indirectly via global partners. Sales increase over time, together with an optimization of operating costs, enables this revised target. At the same time, we must remember that CellaVision will often have large variations in gross margins from quarter to quarter and CellaVision's sales growth will continue to fluctuate quarterly. The financial target of sales growth of 15% over an economic cycle remains", said Zlatko Rihter, CEO of CellaVision.
For fur
ther information, please contact:
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: CellaVision AB via GlobeNewswire
HUG#1934004
|
||
|
||
Copyright 2015 Nasdaq / GlobeNewswire | Back to overview list |